Relmada Therapeutics, Inc. (RLMD)

USD 0.35

(-2.32%)

Market Cap (In USD)

10.66 Million

Revenue (In USD)

-

Net Income (In USD)

-98.79 Million

Avg. Volume

183.55 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.35-7.223
PE
-
EPS
-
Beta Value
0.415
ISIN
US75955J4022
CUSIP
75955J402
CIK
1553643
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Sergio Traversa M.B.A., Pharm.D.
Employee Count
-
Website
https://www.relmada.com
Ipo Date
2014-06-20
Details
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.